Loading
A phase 3 trial in lung cancer, run by Yantai LNC Biotechnology Singapore PTE. LTD., not yet recruiting.
Clinical Study of 18F-Alfatide Injection PET/CT is a phase 3, interventional study registered as NCT06416852 by Yantai LNC Biotechnology Singapore PTE. LTD., with a registry enrolment figure of 428 participants, started 2024-08 and due to reach its primary completion in 2026-08. Interventions recorded: 18F-Alfatide Injection; 18F-FDG Injection. Conditions listed: Non-Small Cell Lung Cancer NSCLC. Primary outcome: Sensitivity and specificity evaluation of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT. Lung eligibility wording from the registry: "Patients with non-small cell lung cancer confirmed or highly suspected by investigators based on prior history, imaging, histopathology, and/or cytology, suspected lymph node metastasis and proposed radical surgery and lymph node dissection;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.